← Sichuan Kelun Pharmaceutical overview

Sichuan Kelun Pharmaceutical vs ANI Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

ANI Pharmaceuticals Inc (ANIP)

Q3 2026
▼3▲1

ANI's Q2 revenue beat but Cortrophin guidance cut and legal loss weigh

  • Record Q2 revenue and $100M buyback ANI reported record Q2 2026 revenue of $266 million, up 25.9% from a year ago, and adjusted earnings per share of $2.21 beat expectations. The board also authorized a $100 million share buyback through 2029, which supports the stock by returning cash to shareholders.

    This is the core positive financial result that drove the quarter and shows the company's underlying growth.

  • Cortrophin guidance cut despite volume growth ANI lowered its 2026 Cortrophin Gel revenue outlook to $520-$540 million from $540-$575 million, and Q2 Cortrophin sales of $117.1 million missed the $120.4 million consensus. This signals weaker-than-expected demand for a key drug and pressures the stock.

    The guidance cut is the main negative event of the period and directly explains why the stock fell after earnings.

  • Full-year guidance misses, stock drops 9.1% Even though Q2 revenue beat estimates by 2.4%, ANI's full-year revenue guidance slightly missed expectations, making it the weakest guidance among four generic drug peers. The stock fell 9.1% to $75.12, reflecting investor disappointment with the forward outlook.

    This captures the market reaction and the relative weakness versus peers, which is central to why the stock moved.

  • Legal setback in CG Oncology royalty dispute A Delaware court denied ANI's motions for a new trial and judgment in its dispute with CG Oncology over a 5% royalty on future sales of cretostimogene grenadenorepvec. ANI will appeal to the Delaware Supreme Court, but the loss threatens a potential royalty revenue stream and adds uncertainty.

    This is a distinct negative legal development that could affect future royalty income and investor sentiment.

July 2026
▼3▲1

ANI's Q2 revenue beat but Cortrophin guidance cut and legal loss weigh

  • Record Q2 revenue and $100M buyback ANI reported record Q2 2026 revenue of $266 million, up 25.9% from a year ago, and adjusted earnings per share of $2.21 beat expectations. The board also authorized a $100 million share buyback through 2029, which supports the stock by returning cash to shareholders.

    This is the core positive financial result that drove the quarter and shows the company's underlying growth.

  • Cortrophin guidance cut despite volume growth ANI lowered its 2026 Cortrophin Gel revenue outlook to $520-$540 million from $540-$575 million, and Q2 Cortrophin sales of $117.1 million missed the $120.4 million consensus. This signals weaker-than-expected demand for a key drug and pressures the stock.

    The guidance cut is the main negative event of the period and directly explains why the stock fell after earnings.

  • Full-year guidance misses, stock drops 9.1% Even though Q2 revenue beat estimates by 2.4%, ANI's full-year revenue guidance slightly missed expectations, making it the weakest guidance among four generic drug peers. The stock fell 9.1% to $75.12, reflecting investor disappointment with the forward outlook.

    This captures the market reaction and the relative weakness versus peers, which is central to why the stock moved.

  • Legal setback in CG Oncology royalty dispute A Delaware court denied ANI's motions for a new trial and judgment in its dispute with CG Oncology over a 5% royalty on future sales of cretostimogene grenadenorepvec. ANI will appeal to the Delaware Supreme Court, but the loss threatens a potential royalty revenue stream and adds uncertainty.

    This is a distinct negative legal development that could affect future royalty income and investor sentiment.

Latest
▼3▲1

ANI's Q2 revenue beat but Cortrophin guidance cut and legal loss weigh

  • Record Q2 revenue and $100M buyback ANI reported record Q2 2026 revenue of $266 million, up 25.9% from a year ago, and adjusted earnings per share of $2.21 beat expectations. The board also authorized a $100 million share buyback through 2029, which supports the stock by returning cash to shareholders.

    This is the core positive financial result that drove the quarter and shows the company's underlying growth.

  • Cortrophin guidance cut despite volume growth ANI lowered its 2026 Cortrophin Gel revenue outlook to $520-$540 million from $540-$575 million, and Q2 Cortrophin sales of $117.1 million missed the $120.4 million consensus. This signals weaker-than-expected demand for a key drug and pressures the stock.

    The guidance cut is the main negative event of the period and directly explains why the stock fell after earnings.

  • Full-year guidance misses, stock drops 9.1% Even though Q2 revenue beat estimates by 2.4%, ANI's full-year revenue guidance slightly missed expectations, making it the weakest guidance among four generic drug peers. The stock fell 9.1% to $75.12, reflecting investor disappointment with the forward outlook.

    This captures the market reaction and the relative weakness versus peers, which is central to why the stock moved.

  • Legal setback in CG Oncology royalty dispute A Delaware court denied ANI's motions for a new trial and judgment in its dispute with CG Oncology over a 5% royalty on future sales of cretostimogene grenadenorepvec. ANI will appeal to the Delaware Supreme Court, but the loss threatens a potential royalty revenue stream and adds uncertainty.

    This is a distinct negative legal development that could affect future royalty income and investor sentiment.